Hormonal
High-dose semaglutide (2.4 mg once weekly) significantly reduces the risk of major adverse cardiovascular events in overweight or obese adults without diabetes who have pre-existing cardiovascular disease.
If you are overweight or obese and have existing heart disease (like a prior heart attack or stroke) but do not have diabetes, high-dose semaglutide (2.4 mg weekly) is a clinically proven intervention to significantly lower your risk of future cardiovascular events, including heart attack and stroke. This benefit is independent of diabetes status and is achieved through a once-weekly injection alongside standard heart medications.
The trial showed a significant 20% reduction of developing a primary cardiovascular end-point in the semaglutide group compared with the placebo group.
Why this rating
The study is a large, multicentre, double-blind, randomized, placebo-controlled trial (SELECT) with over 17,000 patients, published in the New England Journal of Medicine.
Source
High dose semaglutide 2.4 mg (once weekly) shown to reduce the risks of cardiovascular events in people without diabetes
Iskandar Idris · Diabetes Obesity and Metabolism Now · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →